Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board
Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference
Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology
Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
Xenetic Biosciences, Inc. to Present at BIO Investor Forum
Xenetic Biosciences, Inc. Provides Business Outlook
Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform
